Phase 1 randomized double-blind study of an RNA interference therapeutic targeting HSD17B13 for metabolic dysfunction–associated steatohepatitis

Journal:

Journal of Hepatology

Published:

2025-06-28

DOI:

10.1016/j.jhep.2025.05.031

Affiliations:

6

Authors:

10

Go to article

Institutions	Authors	Share
Alnylam, United States of America (USA)	6.000000	0.60
Regeneron Pharmaceuticals, United States of America (USA)	2.000000	0.20
Virginia Commonwealth University (VCU), United States of America (USA)	1.000000	0.10
Richmond Pharmacology, United Kingdom (UK)	0.500000	0.05
City St George's, University of London, United Kingdom (UK)	0.500000	0.05

Interested in Medical Biochemistry and Metabolomics?